Chronic lymphocytic leukemia in Subsaharian Africa: Clinical outcome experience of Côte d'Ivoire;La leucémie lymphoïde chronique du Noir en Afrique subsaharienne: Caractéristiques cliniques thérapeutiques et pronostiques (cas de la Côte d'Ivoire)

Bulletin du Cancer

Volumn 96, Issue 9, 2009, Pages 901-906

  Koffi, K G ^a   Nanho, D C ^a   Tolo, A ^a   N'Dathz, E ^a   Kouakou, B ^a   Meite, N ^a   Ayemou, R ^a   Sanogo, I ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE YOPOUGON   (Côte d’Ivoire)

Author keywords

Black African patients; Chronic lymphocytic leukaemia; Clinical; Survival; Therapeutic

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; COP PROTOCOL 1; HYDROCORTISONE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE;

ADULT; AFRICA; AGED; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PROGNOSIS; REVIEW; ANALYSIS OF VARIANCE; ARTICLE; COTE D'IVOIRE; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SEX RATIO;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; COTE D'IVOIRE; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; HYDROCORTISONE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METHOTREXATE; METHYLPREDNISOLONE; MIDDLE AGED; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; VINCRISTINE;

EID: 70350059215     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2009.0921     Document Type: Review

References (14)

1. Binet JL. French Cooperative Group on CLL prognosis and therapeutical advances in CLL management. Semin Haematol 1987 ; 24 : 275.
2. Yao T, Tea N, Rain JD. La leucémie lymphoïde chronique en Côte d'Ivoire à propos de 69 cas. Med Trop 1991 ; 51 : 417-420
3. Izzia K. Les leucémies lymphoïdes chroniques au Zaïre (Congo Démocratique) à propos de 39 cas. Med Afr Noire 1997 ; 24 : 225-258
4. Hallek M, Bergmann M, Brittinger G, Döhner H, Dreger P, Herold M, et al. Chronic lymphatic leukemia. Curr Ther Concepts 2002 ; 43 : 1245-1254
5. Carlie PM, Maynadie M. La survie des cas d'hémopathies malignes de l'adulte en Europe. Hématologie 2001 ; 7 : 208-213 (Pubitemid 32803364)
6. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplasic disease of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting. J Clin Oncol 1999 ; 17 : 3835-3849
7. Pamuk ON, Pamuk GE, Soysal T, Ongören S, Baslar Z, Ferhanoglu B, et al. Chronic lymphocytic leukemia in Turkey: experience of a single center in Istanbul. South Med J 2004 ; 97 : 240-245 (Pubitemid 38391281)
8. Agrawal N, Naithani R, Mahapatra M, Panigrahi I, Kumar R, Pati HP, et al. Chronic lymphocytic leukemia in India: a clinicohematological profile. Hematology 2007 ; 12 : 229-233 (Pubitemid 46930249)
9. Nenova I, Mateva N, Ananoshtev N, Grudeva-popoya J. The prognostic value of clinical and laboratory parameters in patients with chronic lymphocytic leukemia. Hematology 2005 ; 10 : 47-51. (Pubitemid 41093588)
10. Leporrier M. Pronostic de la leucémie chronique. Presse Med 2001 ; 50 : 2-6.
11. Levy V. Facteurs pronostiques de la leucémie lymphoïde chronique. Hématologie 2000 ; 6 : 219-225 (Pubitemid 30644692)
12. Montserrat E. New pronostic markers in CLL. Haematology Am Soc Hematol Educ Program 2006 : 279-284
13. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukaemia: results from Cancer and leukaemia Group B 9712 (CAL GB 9712). Blood 2003 ; 101 : 6-14. (Pubitemid 36025880)
14. Michallet AS. Actualités thérapeutiques de la leucémie lymphoïde chronique. Bull Cancer 2005 ; 92 : 249-256 (Pubitemid 40562429)